Literature DB >> 35000015

Abnormal connectivity model of raphe nuclei with sensory-associated cortex in Parkinson's disease with chronic pain.

Yalian Shen1,2, Juan Wang1, Juan Peng3, Xiaolin Wu1, Xiaocui Chen1, Jinjin Liu1, Min Wei1, Dezhi Zou1, Yu Han1, Anran Wang4, Oumei Cheng5.   

Abstract

BACKGROUND AND
OBJECTIVE: There are indicates that raphe nuclei may be involved in the occurrence of chronic pain in Parkinson's disease (PD). In the study, we investigated the functional connectivity pattern of raphe nuclei in Parkinson's disease with chronic pain (PDP) to uncover its possible pathophysiology.
METHODS: Fifteen PDP, who suffered from pain, lasted longer than 3 months, sixteen Parkinson's disease patients with no pain (nPDP) and eighteen matched normal health controls (NCs) were recruited. All subjects completed the King's Parkinson's Pain Scale (KPPS) besides Parkinson-related scale and demographics. We performed a seed-based resting-state analysis of functional magnetic resonance imaging to explore whole-brain functional connectivity of the raphe nuclei. Multiple regression model was used to explore the related factors of pain including disease duration, disease severity, Hamilton Depression Rating Scale, age, sex, levodopa equivalent dose and the strength of network functional connectivity.
RESULTS: Compared with the nPDP, the PDP group showed stronger functional connectivity between raphe nuclei and pain-related brain regions, including parietal lobe, insular lobe, cingulum cortex and prefrontal cortex, and the functional connectivity values of those areas were significantly positively correlated with KPPS independent of the clinical variables. Compared with NCs, the combined PD groups showed decreased functional connectivity including prefrontal cortex and cingulum cortex.
CONCLUSIONS: Abnormal functional connectivity model of raphe nuclei may be partly involved in pathophysiological mechanism of pain in PD.
© 2022. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  5-hydroxytryptamine; Chronic pain; Functional connectivity; Parkinson’s disease; Raphe nuclei

Mesh:

Substances:

Year:  2022        PMID: 35000015     DOI: 10.1007/s10072-022-05864-9

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.830


  43 in total

Review 1.  Duloxetine: a review of its pharmacology and use in chronic pain management.

Authors:  Geoff A Bellingham; Philip W H Peng
Journal:  Reg Anesth Pain Med       Date:  2010 May-Jun       Impact factor: 6.288

2.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

Review 3.  Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment.

Authors:  K Ray Chaudhuri; Anthony H V Schapira
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

Review 4.  Non-motor features of Parkinson disease.

Authors:  Anthony H V Schapira; K Ray Chaudhuri; Peter Jenner
Journal:  Nat Rev Neurosci       Date:  2017-06-08       Impact factor: 34.870

5.  Reduced plasma serotonin and 5-hydroxyindoleacetic acid levels in Parkinson's disease are associated with nonmotor symptoms.

Authors:  Qing Tong; Li Zhang; Yongsheng Yuan; Siming Jiang; Rui Zhang; Qinrong Xu; Jian Ding; Daqian Li; Xiaobin Zhou; Kezhong Zhang
Journal:  Parkinsonism Relat Disord       Date:  2015-05-27       Impact factor: 4.891

Review 6.  Prevalence of pain in Parkinson's disease: a systematic review using the modified QUADAS tool.

Authors:  Martijn P G Broen; Meriam M Braaksma; J Patijn; Wim E J Weber
Journal:  Mov Disord       Date:  2012-01-09       Impact factor: 10.338

7.  Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.

Authors:  Estelle Dellapina; Angélique Gerdelat-Mas; Fabienne Ory-Magne; Laure Pourcel; Monique Galitzky; Fabienne Calvas; Marion Simonetta-Moreau; Claire Thalamas; Pierre Payoux; Christine Brefel-Courbon
Journal:  Mov Disord       Date:  2010-10-19       Impact factor: 10.338

8.  The effect of duloxetine on primary pain symptoms in Parkinson disease.

Authors:  Ruth Djaldetti; Shlomit Yust-Katz; Vadim Kolianov; Eldad Melamed; Ron Dabby
Journal:  Clin Neuropharmacol       Date:  2007 Jul-Aug       Impact factor: 1.592

Review 9.  Pain in Parkinson disease: a review of the literature.

Authors:  Ayla Fil; Roberto Cano-de-la-Cuerda; Elena Muñoz-Hellín; Lidia Vela; María Ramiro-González; César Fernández-de-Las-Peñas
Journal:  Parkinsonism Relat Disord       Date:  2012-12-14       Impact factor: 4.891

10.  Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey.

Authors:  Laurence Nègre-Pagès; Wafa Regragui; Didier Bouhassira; Héléne Grandjean; Olivier Rascol
Journal:  Mov Disord       Date:  2008-07-30       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.